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Abstract
The plasma membrane establishes the interface for 
the communication of cells with the environment. Thus, 
surface determinants govern the reactivity and capacity of 
cells to respond to external signals. Changes in their proﬁ le, 
for example in malignant transformation, and manifestation 
of cell-type-specific features apparently hold inspiring 
lessons in store for us on how they are translated into cellular 
responses. But before turning to the signaling routes the 
biochemical modes for coding signals warrant a comment, as 
proteins are often unduly portrayed as the decisive hardware. 
In contrast, and actually prominent among the biochemical 
systems to store information, carbohydrate epitopes of cellular 
glycoconjugates favorably combine high-density coding with 
strategic positioning, rendering them readily accessible for 
interactions with adaptor molecules. The interaction with 
lectins is the ignition key to start glycoconjugate-mediated 
biosignaling. Several plant lectins, especially due to their 
mitogenicity, have become a popular type of laboratory tool 
to elicit cell responses and to analyze biochemical pathways 
leading from initial binding to measured activity such as 
enhanced proliferation. With emerging insights into the 
roles of mammalian (endogenous) lectins and the promising 
perspective for medical applications, emphasis in this area 
is shifting from model studies with plant proteins toward 
work with the physiological effectors. By targeting branch-
end epitopes of glycan chains two classes of endogenous 
lectins, i.e. galectins and selectins, are remarkably well 
suited to establish initial contacts with the cell surface. 
Indeed, these lectins – in their interplay with certain cognate 
binding partners – are being deﬁ ned as potent signal inducers. 
Consequently, we can take aspects of their activity proﬁ les as 
incentive to dissect underlying routes of signal transmission 



































   ©2006 FCCA (Forum: Carbohydrates Coming of Age)
                                      Trends in Glycoscience and Glycotechnology
                                      Vol.18 No.99 (January 2006) pp.1–37
2
details. Hence, regulation of cell growth by cascades of 
mitogen-activated protein kinases (MAPKs), cyclins/cyclin-
dependent kinases and inhibitors thereof, of cell survival by 
the phosphatidylinositol 3
,
-OH kinase (PI3K)/Akt pathway, 
the remodeling of the cytoskeleton by integrin-mediated 
cell adhesion, the implication of p53 in regulating cell fate 
and details of programmed cell death by the intrinsic and 
extrinsic routes for induction of apoptosis will be discussed. 
Moreover, we will look at selectin-induced signaling during 
leukocyte homing. Explicitly, it is the aim of our review to 
familiarize glycoscientists, whose main interest is to scrutinize 
the structural aspects or to develop applications, with basic 
concepts of cellular signaling triggered by these interactions.
A. Introduction
Their chemis t ry confers unique proper t ies to 
carbohydrates for handling biological information. In marked 
contrast to amino acids and nucleotides, the synthesis of linear 
oligomers is in this case not at all restricted to a single way 
to join the individual building blocks. Variability in anomeric 
linkage (α,β) and in the connections via glycosidic linkages 
involving the four pairs of hydroxyl groups at positions 1-2, 
1-3, 1-4, and 1-6 for hexopyranoses is a crucial factor to 
explain the unsurpassed capacity of oligosaccharides to store 
information (1, 2). Thus, the sequence of an oligosaccharide is 
determined by the order of its building blocks and then by the 
way they are linked in the chain. When looking at glycogen 
and cellulose, the importance of the difference between α- 
and β-linkages becomes apparent. Next, the presence of 
several, rather equivalent adaptor points in a monosaccharide 
has a further important consequence. Known from ABH 
blood-group epitopes (3), branching is a common feature 
of glycan epitopes, another appealing structural talent of 
carbohydrates in bioinformatics. This ability for high-density 
coding, “ideal for generating compact units with explicit 
informational properties” (4), is a boon to present a large array 
of biochemical signals within the limited space of the cell 
surface. Automatically, the notion suggesting that spatially 
accessible epitopes at the branch ends of glycan chains such 
as those of the mentioned ABH system are likely relevant to 
serve as code words arises. To meet the demand for generating 
a wide panel of signals, frequent structural variations in this 
region should be detectable, a hypothesis put to experimental 
test using plant lectins in histochemistry. 
Indeed, histochemical monitoring and also structural 
analysis have amply illustrated occurrence of cell-type-
characteristic glycomic profiles, to which the concept of 
the sugar code is now ascribing a functional meaning (5–
23). As a prerequisite to be able to realize the theoretical 
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be present in the cell. Supporting this idea to link glycan 
structures to function (functional glycomics), the predicted 
complex enzymology has in fact developed to introduce a 
conspicuous level of substitutions especially to branch ends 
of glycoconjugates (19, 24–32). In principle, a single enzyme 
would be sufficient to accomplish the addition for example 
of fucose to a glycan chain. To use this letter for generation 
of many code words, one would expect diversity at the level 
of fucosyltransferases. The number of genes for enzymes 
with this activity will thus be a clear sign as to whether 
diversity in sugar code word generation is worth the expense 
in required genomic coding space. In fact, 13 different genes 
for fucosyltransferases have been identified in the human 
genome, the proteins attaching fucose in α1-2, α1-3, α1-4 or 
α1-6 positions to glycans or directly to proteins to establish 
O-fucosylation (33, 34). As fucosyltransferases are just a 
representative example, the requirement to equip the cell 
surface with a large variety of signals is in principle satisﬁ ed. 
Beyond sequence variations, the already enormous molecular 
diversity is even further enhanced by introducing substituents 
such as a sulfate group, a modification whose pivotal 
importance for example in inflammation will be discussed 
in section H. Yet the talents of carbohydrates as “letters” do 
not end with structural variability in two dimensions. In fact, 
carbohydrates also harbor a favorable characteristic in the 
third dimension.
The potency of a biomolecule which is destined 
to serve as ligand and to transmit its encoded information 
underlies the rules of thermodynamics. The sum of entropic 
factors has an inevitable bearing on the affinity of any 
intermolecular recognition. A major contribution in this 
respect stems from the intramolecular ﬂ exibility of the ligand, 
which is arrested by a snug ﬁ t into the cognate lectin
,
s binding 
site. In order to reduce an entropic penalty upon actual 
complex formation with its receptor it is favorable to reduce 
the inherent ﬂ exibility of the ligand. Indeed, oligosaccharides 
qualify as notably suitable ligands in this respect too, because 
their rather bulky pyranose rings can generally be spatially 
accommodated to each other in solution in only a few 
energetically favorable conformations (35–42). They can 
thus be compared to “a bunch of keys” (43), in which only 
distinct key-like conformations are selected in biorecognition 
(42). As a consequence, the noted entropic penalty to arrest a 
ﬂ exible ligand is avoided, and recent examples of differential 
conformer selection for bacterial, plant and animal lectins 
illustrate the way key-like conformations ﬁ t into receptor sites 
and even attest its potential for drug design (36, 44–48).
On the cell surface not only the described three aspects 
of the sugar code (linear sequence and branching as well 
as three-dimensional shape) determine the extent of ligand 
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factors also matter, i.e. the conformational flexibility of the 
chain regulated for example by common glycan substitutions. 
Core fucosylation or the introduction of a bisecting 
N-acetylglucosamine residue appear to act like molecular 
switches in the case of N-glycans to modulate their ligand 
afﬁ nity (49–51). The arrangement in two to six antennae for 
N-glycans, a role model for the glycoside cluster effect (42, 
52, 53), or in clusters typical for mucins and the formation 
of microdomains with the possibility to modulate the glycan 
density are also relevant (54–56). In sum, the astounding 
versatility which the hardware of carbohydrates allows and 
the emerging dimensions of the modulation of information 
transfer are main driving forces to change the perception of 
the virtues of glycans which are often underestimated.
Learning from nature
,
s ways to efficiently modulate 
affinity, spatial factors are also being considered in the 
design of glycoinhibitors (57–68). As implied by using 
terms such as rational affinity regulation or glycoinhibitors 
the complexity of the hardware system to store information 
with the alphabet of sugar units (letters) is matched by an 
elaborated network of receptors, mostly lectins. Starting with 
the discovery that the plant lectin phytohemagglutinin, a 
simple tool to obtain leukocytes from blood by agglutinating 
erythrocytes, is mitogenic for normal leukocytes (69), plant 
lectins have widely served as elicitors of signaling, resulting 
in proliferation of immune and tumor cells, differentiation 
or mediator release from immune cells (70–76). Evidently, 
cell binding and ensuing glycan cross-linking trigger a series 
of signaling events en route to the measured effect (72, 77–
79). With the growing realization that plant lectins take the 
position of proof-of-principle models for glycan functionality 
and that endogenous lectins are key players in cell physiology 
(for summary of functions, please see Table I), the issues to 
delineate the speciﬁ city of cell binding, the topology of glycan 
presentation essential for functionality and the biochemical 
route of signaling are attracting increasing attention. As 
documented in Table I, lectins homing in on branch-end 
glycans, i.e. substituted β-galactosides such as ABH or 
Lewis determinants, are frequently listed. This correlation 
underscores the implied functional importance of the terminal 
epitopes of glycan antennae. Lectins named in Table I as 
extracellular effectors are, among others, members of the 
galectin and selectin families (for further general information, 
please see (80–96)).
Equaling plant lectins as signal inducers, these 
endogenous lectins pique an increasing interest with the 
challenge to fathom intracellular events controlled by lectin-
glycan binding and the long-term perspective to eventually 
exploit the effects of non-immunogenic proteins in the 
clinic. In sum, these developments usher us into a signiﬁ cant 
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phenomenological monitoring to its deﬁ nition as biochemical 
signals. As with the signaling language of peptide growth 
factors (97), the carbohydrate language is contextual and 
combinatory.
In what follows we brieﬂ y discuss basic principles on 
how signaling events can converge and be intertwined as a 
Activity
recognition of stem region of N-glycans, a signal for ubiquitin 
conjugation when accessible in incorrectly folded glycoproteins
ligand-selective molecular chaperones in endoplasmic reticulum (ER)
targeting of misfolded glycoproteins to ER-associated degradation
intracellular routing of glycoproteins and vesicles
intracellular transport and extracellular assembly
inducer of membrane superimposition and zippering (formation of 
Birbeck granules)
cell type-speciﬁ c endocytosis
recognition of foreign glycans (β1,3-glucans, LPS)
recognition of foreign or aberrant glycosignatures on cells(incl. 
endocytosis or initiation of opsonization or complement activation)
targeting of enzymatic activity in multimodular proteins
bridging of molecules
induction or suppression of effector release (H2O2, cytokines etc.)
cell growth control and induction of apoptosis/anoikis




Table I. Functions of animal lectins.
Example of Lectin
F-box proteins Fbs1/2 (Fbx2/FBG1, Fbx6b/FBG2) as a ligand-
speciﬁ c part of SCF ubiquitin ligase complexes
calnexin, calreticulin
EDEM/Mnl1 (Htm1)
ERGIC-53 and VIP-36 (probably also ERGL and VIPL), P-type 
lectins, comitin
non-integrin 67 kDa elastin/laminin-binding protein
langerin (CD207)
hepatic and macrophage asialoglycoprotein receptors, dendritic cell 
and macrophage C-type lectins (mannose receptor family members 
(tandem-repeat type) and single CRDa lectins such as langerin/
CD207), cysteine-rich domain of the dimeric form of mannose 
receptor for GalNAc-4-SO4-bearing glycoprotein hormones in 
hepatic endothelial cells, P-type lectins 
CR3 (CD11b/CD18), dectin-1, Limulus coagulation factors C and G, 
earthworm CCF
collectins, L-ﬁ colin, C-type macrophage and dendritic cell receptors, 
α/θ-defensins, pentraxins (CRP, limulin), tachylectins
acrosin, Limulus coagulation factor C
homodimeric and tandem-repeat-type galectins, cytokines (e.g. IL-2:
IL-2R and CD3 of TCR), cerebellar soluble lectin
galectins, selectins and other C-type lectins such as CD23, BDCA-2 
and dectin-1
galectins, C-type lectins, amphoterin-like protein, hyaluronic acid-
binding proteins, cerebellar soluble lectin
selectins and other C-type lectins, I-type lectins, galectins, hyaluronic 
acid-binding proteins (RHAMM, CD44, hyalectans/lecticans)
selectins and other C-type lectins (e.g. DC-SIGN), galectins, I-type 
lectins (e.g. siglecs, N-CAM, P0 or L1)
galectins, heparin- and hyaluronic acid-binding lectins including 
hyalectans/lecticans, calreticulin
proteoglycan core proteins (C-type CRD and G1 domain of 
hyalectans/lecticans), galectins (e.g. galectin-3/hensin), non-integrin 
67 kDa elastin/laminin-binding protein 
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general introduction which is then followed by case studies 
on lectin-dependent signaling. They epitomize the signaling 
concept of the sugar code.
B. Principles of Cell Signaling
It is instructive to first look at principles for the 
definition of information, because its transfer can occur in 
various biochemical forms, e.g. from a glycan to a lectin 
and then passed on to intracellular pathways using cascades 
of phosphorylation. An appealing consensus thesis in the 
fundamental sense is that information is physical in nature, as 
defined by the late Rolf Landauer. A distinguished member 
of the computer science community mainly charting the 
fundamental physical limits of computation, he summarized 
his position in a seminal article published in May of 1991 in 
the journal Physics Today (98). In this context, but within the 
realm of biology, it is reasonable to deﬁ ne cell signaling as 
information transfer along strategically positioned modules. A 
measurable change in a biochemical parameter after the initial 
recognition step embodies the directional ﬂ ow of information. 
Explicitly, a ligand-induced change of conformation (please 
note that a sugar ligand can alter a lectin
,
s shape in solution, 
as demonstrated by small angle neutron scattering (99)) or of 
spatial vicinity by clustering (100) is converted into a different 
“biochemical language”. A panel of means of intermolecular 
communication is at a cell
,
s disposal: a) changes in 
the concentration of components involved in signaling 
pathways (i.e. extracellular ligands for cell surface receptors 
or intracellular second messengers such as Ca2+, cyclic 
nucleotides and phosphoinositides), b) physical interactions 
between diverse signaling components (i.e. protein-protein, 
protein-phosphoprotein or protein-phospholipid interactions, 
among others), c) subsequent conformational changes of 
macromolecules (i.e. allosteric or non-allosteric intramolecular 
rearrangements of signaling proteins) or d) chemical changes 
of signaling components (i.e. posttranslational modiﬁ cations 
of proteins such as phosphorylation, O-GlcNAcylation, 
acylation or methylations, among others). In our context, 
the initial signal can also be altered by glycan remodeling 
at the cell surface, which alters a code word
,
s meaning. 
Depending on the connection of the initial response element 
to intracellular pathways, one or several routes of information 
flow in different languages are possible. This complex 
scenario explains why it should not be expected that a lectin 
will elicit the same response proﬁ le in different cell types.
The basic elements forming a simple signaling chain 
initiated by a stimulus are a signal-receiver/receptor, a signal-
transducer and a signal-amplifier (101). The signal-receiver 
defines its nature due to specific molecular interactions 
between the ligand and its receptor (i.e. protein-protein or 
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Introduction) or by a chemical modification of the receptor 
(i.e. light-induced isomerisation of a prosthetic group in 
a photoreceptor such as the 11-cis-retinal to all-trans-
retinal conversion in rhodopsin) (102). Directional flow 
of information reaches the transducer. This is responsible 
to translate the binding event into a readily propagated 
chemical reaction (i.e. GDP/GTP exchange in target proteins 
or protein phosphorylation events usually carried out by 
specific kinase cascades as we will discuss below), while 
the amplifier enhances the intensity and/or duration of the 
generated signal (i.e. the increased concentration of second 
messengers such as Ca2+ by the opening of Ca2+ channels, of 
cyclic nucleotides by the activation of adenylate/guanylate 
cyclases or of phosphoinositides by the activation of speciﬁ c 
phospholipases, to name a few examples that will be explained 
below). Finally, the signal-effector at the signaling chain
,
s end 
triggers the cellular function (e.g. the production of light by 
the luciferine/luciferase system, cell migration mediated by 
cytoskeletal reorganization or the expression of genes under 
the control of a particular set of transcription factors). As a 
reﬁ nement of this elementary system, signal-modulators are 
implemented as feedback and/or feed-forward control of the 
pathway enhancing or decreasing the impact of the signaling 
event (e.g. regulatory protein kinases and phosphatases which 
modulate the activity of major proteins in signaling pathways 
or proteases which degrade and therefore remove signaling 
proteins at a distinct time of physiological relevance).
Albeit we knowingly have simpliﬁ ed the complexity, 
this basic scheme is helpful as an Ariadne
,
s thread when 
faced with multifarious events triggered by a lectin. To give 
an example on refinements necessary to let our model fit 
reality we mention a case where the roles of receptor and 
ligand are mutually interchangeable for two interacting 
molecules on the surface of adjacent cells, because both of 
them generate signaling events in the corresponding cell, 
i.e. the Eph (erythropoietin-producing human hepatocellular 
carcinoma cell receptors) receptor/ephrin system (103, 104). 
In another occasion, the common sequence of events in which 
the message travels from a receptor to a transducer and ﬁ nally 
to an amplifier is subverted. In the case of the receptor for 
epidermal growth factor (EGFR) its activation by one of its 
multiple ligands will generate a transient Ca2+-ﬂ ux (105), and 
a canonical sequence of events can be predicted: from the 
receptor (EGFR) to the transducer (i. e. the phospholipase Cγ
which produces inositol-1,4,5-trisphosphate) and then to the 
ampliﬁ er (the cytosolic Ca2+ level increases, because inositol-
1,4,5-trisphosphate opens Ca2+ channels in the endoplasmic 
reticulum). In contrast, when a glutamate receptor which 
itself is a Ca2+-channel protein is activated upon binding of 
its ligand (106), the sequence of events is now shortened, and 
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directly to the amplifier (the Ca2+ level rising due to the 
activity of the intrinsic channel component of the receptor).
As known from sociology, information processing is 
not an isolated process. The intricacies and interconnections 
of the multiple signaling pathways of the cell together with the 
regulation on the level of the signal receiver account for the 
observed pleiotropicity in cell responses and the observation 
that cells may only be responsive in a particular spatiotemporal 
situation (77, 78). As we will discuss below, only activated T 
cells undergo galectin-dependent apoptosis, whereas resting 
cells are protected. As emphasized recently (107), caution is 
to be exercized to draw predictions of events from knowledge 
on interconnections without thoroughly considering the details 
of the given case. Having so far looked at the components of 
signaling cascades, we will now brieﬂ y comment on routes.
A signal from the extracellular space can be routed 
into the cell interior in a mono-directional or bi-directional 
manner (78). In the first case, the mono-directional signal 
ﬂ ow can start from different settings: a) a free growth factor 
such as the mature EGF inducing receptor dimerization or a 
lectin binding and cross-linking surface glycans (the case of 
certain cytokines illuminates linking of receptor-binding and 
lectin activities for combined target selectivity (108, 109)), 
b) a growth factor still attached to the plasma membrane of 
a neighboring cell such as the precursors of the TGF-α/β
(transforming growth factors α/β), where its positioning on 
the cell suface in a suitable manner for proteolytic activation 
depends on a protein-carbohydrate interaction involving a 
P-type lectin and a mannose-6-phosphate group as molecular 
postal code for TGF-β (110), and c) matrix-bound proteins 
such as fibronectin, laminin, vitronectin and collagen, each 
one engaging their cognate receptors but often also interacting 
with endogenous lectins as non-integrin-type binding partners 
(111-113). The receptors for the peptide motif are located in 
the plasma membrane of the responsive cell, the interface 
of signal transfer to the cytoplasm. In the second case, bi-
directional signaling occurs between two neighboring cells. 
Upon contact, homotypic molecules such as cadherins (114, 
115) or heterotypic molecules such as Eph receptors and 
ephrins (103, 104) or pairs of lectin-glycan binding partners 
are recruited for building molecular bridges, and both cells 
transduce these mutual signals by potentially divergent 
signaling pathways into their interior, leading to coordinated 
but divergent responses. As further example for bi-directional 
signaling routes, the direct exchange of second messengers 
such as Ca2+, cyclic nucleotides and phophoinositides between 
the cytosols of connected cells is possible via intercellular gap 
junction channels formed by connexins (116).
For signaling, convergence is a key step. It enables 
different intracellular pathways to meet by common signaling 
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by their ligands such as a tyrosine kinase receptor (i.e. the 
EGFR by EGF) (112) and a G-protein-coupled receptor (i.e.
the lysophosphatidic acid receptor by lysophosphatidic acid) 
(117) as well as integrins upon engagement with cognate 
extracellular matrix proteins (118) all activate the Ras/
MAPK pathway (please see Fig. 1 for additional details). 
Furthermore, the way we look at integrins has been subject 
to a significant broadening. Initially described as receptors 
for an extracellular matrix component via protein-protein 
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Fig. 1. Signaling by mitogen-activated protein kinase pathways. Activation of a large set of cell surface receptors including 
receptor tyrosine kinases (RTKs), selectins (SELs), integrins (INTs), G protein-coupled receptors (GPCRs), death receptors (DRs) 
and cytokine receptors (CRs), among others, triggers four major mitogen-activated protein kinase (MAPK) pathways. They engage 
intermediary biochemical switches from the family of small G proteins (sGPs) as for example Ras, Rap1, Rac, Rho, and Cdc42. The 
inactive GDP-containing G protein is converted to its active form with GTP instead of GDP by a guanine nucleotide exchange factor 
(GEF), and the reverse reaction is catalyzed by the intrinsic GTPase activity of the G protein. GDP production is accelerated by a 
GTPase-activating protein (GAP). The active G protein initiates signal transfer by the protein kinase cascade. It starts with a MAPK 
kinase kinase (MAPKKK), proceeds to a MAPK kinase (MAPKK) and then reaches the MAPK level by sequential phosphorylations. 
The four independent pathways described regulate: a) the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2); b) the 
p38MAPK α, β and γ; (p38α/β/γ); c) the c-Jun N-terminal kinases 1, 2 and 3 (JNK1/2/3) and d) the extracellular signal-regulated 
protein kinase 5 (ERK5). The upstream MAPKKs implicated in these pathways are the MAPK/ERK kinases 1 and 2 (MEK1/2), 
the MAPK kinases 3 and 6 (MKK3/6), the MAPK kinases 4 and 7 (MKK4/7) and the MAPK/ERK kinase 5 (MEK5), respectively. 
Further upstream at the level of the MAPKKKs we ﬁ nd the kinases c-Raf, Raf-A or Raf-B (A/B/c-Raf), the mixed lineage kinase 3 
(MLK3) among others, the MEK kinases 1 and 4 (MEKK1/4) and the MEK kinases 2 and 3 (MEKK2/3), respectively. Additional 
upstream MAPKKK kinases which communicate with G proteins could also be a part of the signaling cascade (not shown here). The 
targets of the diverse MAPKs, directly or via further interposed accessory protein kinases, are a deﬁ ned array of transcription factors 
(TFs). Hereby, speciﬁ c modulation of the level of gene transcription results in desired biological responses such as proliferation, 
differentiation, apoptosis, cell adhesion or inflammatory responses. Examples for transcription factors or co-transcriptional 
modulators involved are the Stat1/3 (signal transducer and activators of transcription 1 and 3), c-Myc, c-Fos, Sp1, Elk-1, CREB 
(cAMP-responsive element binding protein), c-Jun, p53, NF-κB (nuclear factor κB), NF49 IL6 (nuclear factor for interleukin 6), and 
Smad. Selected examples for roles of galectins (Gals) in this system are indicated (please see text for details).
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(as we will see below) and a lectin via its I domain, as proven 
for αMβ2-integrin (CR3, CD11/CD18b, Mac-1) (119, 120). 
Intriguingly, a single signal-initiation element, EGFR for 
example, can feed different signals into divergent signaling 
pathways such as the activation of both the mitogenic Ras/
MAPK pathway (121) and the cell survival PI3K/Akt pathway 
(122, 123), both activated by this receptor (please see Fig. 1 
and Fig. 4 for further details). What has been unravelled for 
peptide growth factors is now beginning to turn up also when 
examining lectins as signal inducers. So far, our discussion 
raises the impression that important signals invariably came 
from the extracellular space. For the proper understanding of 
the intimately integrated function of the cell machinery we 
must yet not neglect the importance of intracellularly initiated 
signaling. Mitochondria, the cytoplasm and the nucleus are all 
active compartments in this respect. The emerging functional 
relevance of translocation of extracellular growth factors, 
cytokines and even plasma membrane-bound receptors from 
the cytosol to the nucleus has been described recently (124, 
125). Of note, we wish to sensitize the reader to the idea that 
a certain effector such as a lectin can have more than one 
function in signaling. Members of the galectin family will 
serve as instructive examples to illustrate this point.
Having herewith outlined principles of signaling, we 
now proceed to the case studies on the involvement of lectins 
in signaling pathways. Our selection has been guided by 
the aim to place emphasis on routes crucial for the control 
of important cellular functions such as cell proliferation, 
survival, intercellular recognition, motility, differentiation and 
apoptosis/anoikis.
C. The Mitogen-Activated Protein Kinase (MAPK) Pathways
As the definition already implies, this signaling 
cascade of phosphorylation events was originally detected 
as intracellular response to receiving mitogenic signals at 
the cell surface. As shown in Fig. 1, a panoply of receptors 
is engaged in transmitting respective signals from the cell 
surface across the membrane (126). When reading the term 
“integrins”, we have indicated above that protein-protein 
interaction is only a part of these glycoproteins
,
 functional 
spectrum. Thus, they should be considered to act as sensors 
for peptide motifs in cognate ligands and for lectins binding 
their glycans (please see below). Following an integration 
step involving small G proteins at the cytoplasmic side of 
the membrane as transducers, the cascades branch and reach 
several effectors, namely extracellular signal-regulated 
kinases (ERKs), p38MAPKs and c-Jun N-terminal kinases 
(JNKs), the latter also known as stress-activated protein 
kinases (SAPKs). Their enzymatic activity, posttranslationally 
modifying transcription factors, gives gene expression the 
required direction to respond adequately to the incoming 
のとして記載されたが、グリカンを介したセンサーともなり
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signal. In detail, the ERK1/2(MAPK) (121), the p38MAPK 
(127, 128), the JNK(MAPK) (129), and the ERK5(MAPK) 
(130) pathways can act combinatorially to accomplish fine-
tuning and integration of diverse signals. For this purpose, 
the initial integration step at the level of small G proteins 
of the Ras and related families is subject to intimate control 
mechanisms. A dynamic equilibrium between the inactive 
(GDP-containing) and active (GTP-containing) forms of a G 
protein is maintained by guanine nucleotide exchange factors 
(GEFs), which catalyze the formation of the active form, 
and GTPase-activating proteins (GAPs), which increase the 
intrinsic GTPase activity of the G protein and hereby produce 
the GDP-containing inactive form (131). Of note, the speciﬁ c 
introduction of mono-O-glucosylation at a single threonine 
residue of small GTPases such as Rho, Rac, Cdc42 or R-Ras 
is the common mode of action of large clostridial cytotoxins 
(132). This modification by the bacterial toxin inactivates 
the versatile signal transducers and hereby impairs various 
signaling pathways. The case studies on plant lectins as 
mitogens for B and/or T lymphocytes have shown that glycan 
binding and clustering can make its mark on proliferation 
(75). Starting with the mitogenic effect of chicken and eel 
galectins on mouse/rabbit lymphocytes (133–135), the studies 
were then extended to the effect of mammalian galectin-1 
on smooth muscle and hepatic stellate cells (136–139) and 
also to galectin-3. Albeit being predominantly monomeric 
in solution, galectin-3 forms pentamers with suitable glycan 
display to cross-link cell surface glycoligands (65, 140). When 
acting on fibroblasts, this process engenders growth with 
potential relevance in angiogenesis and cardiac ﬁ brosis (141, 
142). To give an example for a clinically relevant endpoint of 
signaling initiated by a lectin, galectin-3 not only stimulates 
proliferation of cardiac ﬁ broblasts but also enhances collagen 
I production under the control of the transcription factor 
Sp1 (142). Deposition of this rather stiff fibrillar protein is 
likely to promote fibrosis what contributes to explain the 
correlation of galectin-3 expression to heart dysfunction 
in hypertrophy (142). In these given instances, the lectin 
binds to a cell surface ligand such as an integrin of the β1-
subfamily en route to the final response, in hepatic stellate 
cells using the MEK1/2-ERK1/2 pathway ((139); please 
see left side of Fig. 1). The α3β1 and α6β1 integrins are the 
targets for the tandem-repeat-type galectin-8 to convey the 
initial message to CHO cells to form F-actin microspikes via 
GTP loading onto Ras and phosphorylation of ERK1/2 (143, 
144). Clearly, cytoskeletal remodeling, as likewise operative 
in glioblastoma cells as invasion-promoting process under 
direction of galectin-1 ((145, 146); please see section D and 
Fig. 3 for further information), is as effectively regulated 
by lectin signaling as is cell proliferation. These results also 
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なら MEK1/2-ERK1/2経路を使っている（139）） （図 1の左半分
を参照）。α3β1 および α6β1 インテグリンはタンデムリピート
型のガレクチン -8の標的であり、CHO 細胞に対する最初の






（145､146）（詳細は D 項および図 3を参照）。これらの結果か
ら、インテグリンやレクチン反応性のグリカン決定基を持つ
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(and also other cell surface glycoproteins with lectin-reactive 
glycan determinants; (111)) as bifunctional molecules with 
interaction sites in protein and glycan moieties, the latter ones 
being sensed, for instance, by galectins. Fittingly, expression 
levels of galectins are themselves under intricate control. In 
the case of galectin-3 the culture conditions in vitro and more 
speciﬁ cally the effectors H-Ras, p53, Jun, NF-κB and growth 
factors such as nerve growth factor (NGF) are regulators 
with the Ras/MAPK pathway involved in controlling this 
gene
,
s activity (147–152). Beyond galectins other lectins are 
similarly regulated, the modulation of transcriptional control 
of selectins by pro-inﬂ ammatory cytokines or of the tandem-
repeat-type macrophage mannose receptor by interleukin-4 
being cited as examples (153, 154). Ras-dependent signal 
transfer can reach the nucleus via the MEK1/2-ERK1/2 
pathway and/or the p38MAPK pathway depending on the 
cell type (macrophage differentiation of THP-1 cells or 
differentiation of phaeochromocytoma cells (151, 152); please 
see Fig. 1 for details). The MAPK pathway is also responsible 
for inducing the expression of a lectin from a different 
family, as for example the asialoglycoprotein receptor of 
macrophages, following treatment with phorbolester, a protein 
kinase C activator (155).
Thus, these lectins are signal inducers by glycan 
binding following secretion and cell surface binding and 
objects of gene regulation during differentiation, and there 
is a further dimension in the activity proﬁ le. As underscored 
by recent measurements with peptide libraries, galectin 
functionality is not restricted to their lectin activity but can 
include peptides as ligand (156–159). Monitoring the binding 
of labeled galectins as histochemical tools reveals intracellular 
staining, in agreement with its presence and function within 
the cell (10, 160–168). Among peptide ligands for galectin-3, 
several proteins including Bcl-2, Alix/AIP-1, Gemin4, CBP70, 
Chrp, synexin, TTF-1, nucling, Sufu and β-catenin have 
shown up in respective searches (156, 159, 169–171). In this 
context, the role of galectin-1, a transforming agent (172, 
173), for the proper placement of oncogenic H-Ras at the cell 
membrane signiﬁ es activity at different sites in the cell.
Intracellular galectin-1 has been shown to interact 
with H-Ras(12V), an oncogenic constitutively active variant 
of H-Ras, and promotes the farnesyl-moiety-dependent 
anchorage of Ras-GTP to the plasma membrane activating 
the MAPK(ERK) pathway (173). In detail, this galectin 
stabilizes H-Ras interactions to non-raft microdomains (174). 
As a consequence, H-Ras/galectin-1 and K-Ras4B/galectin-1 
co-transfectants both present enhanced and prolonged EGF-
dependent increase of active Ras-GTP and MAPK(ERK) 
stimulation, but decrease EGF-dependent phosphoinositide 
3-kinase (PI3K) stimulation (175) (please see separate 












































H-Ras/ガレクチン -1または K-Ras4B/ガレクチン -1の同時形
質導入を受けた細胞では、EGF 依存性の活性型Ras-GTPおよ
び MAP K（ERK）K が持続的に増強される。しかし EGF 依存性
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A galectin-1 mutant with a leucine to alanine substitution 
at posit ion 11, designed by modeling of an assumed 
lipid(farnesyl)-binding site for H-Ras, with unaffected 
carbohydrate-binding capacity inhibits both the formation 
of Ras-GTP and the activation of the MAPK(ERK) pathway 
(176). In addition, this lectin mutant impairs placement of 
H-Ras(G12V) in microdomains of the plasma membrane, 
hereby attenuating cell transformation by this oncogenic 
variant protein (176). Underscoring the general importance 
of this aspect of galectin functionality, the chimera-type 
galectin-3 shows selectivity for activated K-Ras (177). 
Signaling encompasses Raf-1 and PI3K activation and 
attenuation of ERK activity, an indication for selectivity of 
downstream effects inherent to Ras-galectin interplay (177).
The given example of an intracellular impact of 
galectins at the integration step of the cascade shown in Fig. 1 
is not the only so far known case for a lectin affecting distinct 
MAPK pathways. Galectin-7, a homodimeric homologue 
of galectin-1 referred to as p53-induced gene-1 (178, 179) 
(please see section F and Fig. 5 for further information), 
enhances JNK but not p38MAPK activity after transfection 
into HeLa cells, a step toward accomplishing its pro-apoptotic 
activity (180). The way galectins influence the MAPK 
pathways at different sites warrants a summarizing statement: 
distinct cell surface glycan epitopes, for example those from 
integrins or gangliosides, are encoded signals read by lectins. 
Hence, the ensuing message, originating from carbohydrate-
dependent binding, can follow the route via small G proteins 
to the MAPK pathways, which eventually modulate gene 
transcription in a quantitative and qualitative manner. 
Moreover, lectin effectors such as galectins are themselves 
under transcriptional control by these signals. These pathways 
affect as diverse activities as proliferation, differentiation, 
cell adhesion/attachment and cell migration. Furthermore, 
galectins influence the signaling capacity by intracellular 
interaction with oncogenic H-Ras proteins or regulation 
upstream of JNK, as we have outlined above.
Besides galectins, the potency of selectins which are 
depicted in Figs. 1 and 7, and glycosaminoglycan/hyaluronan 
receptors to regulate adhesion and migration via Rac1/2 and 
JNK, ERK1/2 or p38MAPK attests the versatility both for 
the induction of signaling along MAPK pathways and the 
exploitation of individual routes by various glycan epitopes 
(79, 85, 181–185). Looking more closely at proliferation, 
mammalian lectins can affect cell cycle control, an aspect that 
warrants a detailed analysis of the underlying biochemical 
mechanisms in the next section.
D. Cell Cycle Control
Progression of the cell cycle to its S-phase, when 
DNA synthesis takes place, is under the control of the 
のホスホイノシチド 3-キナーゼ（PI3K）促進は低下する（175）
（PI3K については E 項および図 4を参照）。H-Rasの脂質部分
（ファルネシル基）に対する結合部位と考えられている 11位の
ロイシンをアラニンに変えた変異ガレクチン -1は、糖結合活







































細胞周期の DNA合成開始 S 期への移行は、レチノブラ
ストーマタンパク質（pRb）および同じファミリーの関連タン
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retinoblastoma protein (pRb) and related proteins of the 
same family (p107 and p130). This protein is subject to 
phosphorylation, a process that has a marked impact on 
its activity (please see Fig. 2 for details). The enzymes 
responsible for these phosphorylations are cyclin-dependent 
kinases (CDKs). Their activity is modulated by cyclins, the 
regulatory subunits of these kinases. As this name implies, 
they undergo an oscillatory expression during the different 
phases of the cell cycle. pRb acts as a transcriptional inhibitor, 
affecting different transcription factors, among them E2F. 
Predictably, a host of genes with functions in cell cycle 
control or DNA replication is regulatable by E2F (186). Upon 
phosphorylation by cyclin-dependent kinases (CDK4/6 and 
CDK2), which are activated by diverse cyclins (CycD1/2 and 
CycE, respectively), pRb is released from the complex with 
E2F. Hereby, gene expression of proteins relevant for G1/S 
transition, the progression to the S-phase and cell proliferation 
are no longer blocked. In this interplay, the downregulation 
of diverse cyclin-dependent kinase inhibitors (CKIs) is also 



















































Fig. 2. Cell cycle control by the retinoblastoma protein. The cooperation between a receptor tyrosine kinase (RTK) activated 
by a growth factor and integrins (INTs) upon interaction with extracellular matrix (ECM) glycoproteins such as ﬁ bronectin or laminin 
generates signaling events which result in the expression of cyclins D1 and D2 (CycD1/2). They also cause the downregulation of 
different types of cyclin kinase inhibitors (CKIs): p21cip1/waf1, p27kip1 and p57kip2, which act on cyclin-dependent kinase 2 (CDK2) as 
well as p15ink4b, p16ink4a, p18ink4c and p19ink4d, which affect cyclin-dependent kinases 4 and 6 (CDK4/6). The formation of the CycD1/2- 
CDK4/6 plus the CycE-CDK2 complexes leads to phosphorylation of the retinoblastoma protein (pRb) by CDK4/6 and CDK2. 
This modiﬁ cation of pRb impairs its activity as inhibitor of the transcription factor E2F. Having harmed the negative regulator, gene 
expression, especially of cyclin A (CycA), is made possible by this transcription factor. The ensuing formation of the CycA-CDK2 
complex favors the progression of the cell cycle to its S-phase. Selected examples for roles of galectins (Gals) in this system are 
indicated (please see text for details).
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without surprise that this network is altered in tumor cells 
(187, 188). The CKIs are divided into two families – INK4 
and CIP1/KIP2 – which inhibit either CDK4/6 or CDK2 and 
additional CDKs. Fig. 2 depicts the fundamental role of pRb 
during the G1/S transition induced by the cooperative signaling 
of tyrosine kinase receptors and integrins mediating contact to 
the extracellular matrix. Due to its central role in preventing 
unrestricted cell proliferation, pRb is also referred to as a 
tumor suppressor (189). The CKIs such as p16ink4a among 
others also have this status. Notably, this CKI, similar to CIP/
KIP proteins (190), has functions beyond inhibiting CDKs, in 
this case upregulating the ﬁ bronectin receptor (α5β1 integrin) 
(191).
The connection to integrins, illustrated in Fig. 2, and 
the mentioned aspect of p16ink4a functionality has prompted 
to examine whether growth regulation is exerted via this 
pathway. In fact, galectin-1 – by binding to glycans of the 
fibronectin receptor – can cause the arrest of the cell cycle 
at its G1 phase, funneling the signal via the Ras/MEK/
ERK1/2 pathway inhibition to Sp1 and increased p27kip1
presence which then blocks CDK2 activity (192). In line with 
experiments by atomic force microscopy measuring rupture 
forces in the range of 34-37 pN for this lectin in complex with 
glycoligands galectin-integrin interplay in this case is more 
suited for signaling than adhesion (193), as also noted above 
for galectin-3 (142). This member of the galectin family can 
also trigger effective modulations in the cell cycle network 
(please see Fig. 2 for details). Working with transfected tumor 
腫瘍細胞では変化している（187､188）。CDK 群は、INK4 お
よび CIP1/KIP2という2つのファミリーに分かれ、それらは








































Fig. 3. Integrin-mediated cytoskeleton dynamics. Polymerization of globular actin (G-actin) forming ﬁ brillar actin 
(F-actin) occurs at the barbered end (+) of these ﬁ brils, a process that is modulated by the Arp2/3 complex, a nucleator 
of the polymerization process. Arp2/3 is in turn under the control of the Wiskott-Aldrich Syndrome protein (WASP). The 
engagement of integrins (INTs) with glycoproteins from the extracellular matrix (ECM) induces the attachment of ﬁ brilles 
from the actin cytoskeleton to points of adhesion of the cell to the substratum. A panel of adaptor proteins such as talin and 
vinculin (Vincu), among others, bridge points of focal adhesions with F-actin. The dynamics of the actin cytoskeleton at 
the level of these adhesion points is modulated by a series of tyrosine kinases such as the focal adhesion kinase (FAK) and 
c-Src as well as a serine/threonine kinase named integrin-linked kinase (ILK), and also a set of small G proteins such as Rho, 
Cdc42 and Rac. Selected examples for roles of galectins (Gals) in this system are indicated (please see text for details).
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cells increased CycD1 expression and inhibition of anoikis 
by cell cycle arrest at G1 via p21
cip1/p27kip1 upregulation 
and downregulation of CycE and CycA were determined, 
cellular responses which favor malignancy in overexpressing 
breast cancer cell lines tested (194–199). Of relevance, 
these regulatory events should not only be interpreted in the 
framework of Fig. 2, when considering consequences for the 
malignant phenotype. Regarding p27kip1 its cytosolic presence 
also affects cell migration via the small G protein RhoA, a 
process that may contribute to the invasiveness and metastasic 
spread of tumor cells (200). For a galectin as effector, 
remodeling the actin cytoskeleton of high-grade asctrocytoma 
cells suited for invasion was correlated to enhanced expression 
of RhoA, another example for a lectin markedly regulating 
cytoskeletal organization (146) (please see Fig. 3 and its 
legend for details). This case documents a clinical correlation 
between galectin and tumor invasion/survival in animal 
models (145, 146). It also illustrates the complexity of protein 
functions initially considered to be assigned to only one 
distinct task and underscores the need to exercize caution to 
derive simple conclusions from particular experimental data. 
In the regulation of both the cell cycle and cell survival the 
central role of the PI3K pathway, already alluded to above, 
warrants further discussion, which will be given in the next 
section.
E. Signaling by Phosphoinositides
In order to illustrate the noted aspect of an active cross-
talk occurring in the cell among different signaling pathways 
the phosphoinositides pathway provides an attractive example. 
As shown in Fig. 4, this signaling route also reaches the 
CKIs p21cip1/p27kip1 negative regulators of the cell cycle, as 
discussed above and depicted as well in Fig. 2. Among the 
signal receivers at the cell surface, receptor tyrosine kinases 
(RTKs), cytokine receptors (CRs), integrins (INTs), G protein-
coupled receptors (GPCRs), the B-cell receptors (BCRs) 
or the T-cell receptor (TCR)-CD3 complex transmit their 
information to the phosphoinositide 3-kinase (PI3K)/Akt 
protein kinase B (Akt/PKB) system (201-205). Fig. 4 shows 
that the primary components of this system are PI3K (122), a 
producer of phosphatidyl inositol 3-phosphate (PtdIns-3-P), 
phosphatidyl inositol 3,4-biphosphate (PtdIns-3,4-P2), and 
phosphatidyl inositol 3,4,5-triphosphate (PtdIns-3,4,5-P3), 
as well as Akt/PKB (123). This latter kinase is recruited, by 
its pleckstrin homology (PH) domain, to the cell membrane 
presenting suitable phophoinositides. Other important 
players in this system are the 3
,
-phosphoinositide-dependent 
kinase-1 (PDK-1), which also associates, via its PH domain, 
to phosphoinositides when exposed on the cytosolic side of 
the cell membrane, leading to its enhanced phosphorylation 




























（INT）、G タンパク質共役レセプター群（GPCR ）、B 細胞レセ
















                                      Trends in Glycoscience and Glycotechnology
                                      Vol.18 No.99 (January 2006) pp.1–37
17    ©2006 FCCA (Forum: Carbohydrates Coming of Age)
phosphatase A2 (PPA2), which targets Akt/PKB as substrate 
to switch off its activity.
Activation of Akt/PKB induces cell survival. It has 
an antiapoptotic effect and also induces cell cycle arrest. As 
shown in Fig. 4, these pleiotropic effects are modulated as 
follows: a) the arrest of cell proliferation is due to upregulation 
of the CKIs p21cip1/waf1 and p27kip1 (please see Fig. 2 for further 
details), and b) the inhibition of apoptosis is either due to 
upregulation of Mdm2, a regulatory protein involved in the 
degradation of the tumor suppressor p53 (please see also Fig. 
5), or the inhibition of caspase-9 and the pro-apoptogenic 
regulatory protein BAD, an inhibitor of Bcl-XL, a major anti-
apoptotic effector (please see also Fig. 6). Recent studies 
have shed light on endogenous lectins affecting this signaling 
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Fig. 4. Survival signals induced by the PI3K/Akt system. Stimulation of an array of cell surface receptors including receptor 
tyrosine kinases (RTKs), cytokine receptors (CRs), integrins (INTs), G protein-coupled receptors (GPCRs), B-cell receptors (BCRs) 
and the T-cell receptor/CD3 complex (TCR/CD3) stimulate phosphoinositide 3-kinases (PI3Ks). Its activity produces several types 
of phosphoinositides, i.e. phosphatidyl inositol 3-phosphate (PtdIns-3-P), phosphatidyl inositol 3,4-biphosphate (PtdIns-3,4-P2) and 
phosphatidyl inositol 3,4,5-triphosphate (PtdIns-3,4,5-P3). Their presence in cell membranes will recruit proteins containing pleckstrin 
homology (PH) domains to this site. The serine/threonine kinase Akt, also named protein kinase B (Akt/PKB), and 3ʼ-phosphoinositide-
dependent kinase-1 (PDK-1) both associate to the cell membrane by this mechanism, and PDK-1 phosphorylates Akt/PKB. This 
modification induces its activation and hereby that of its protein substrates. Dephosphorylation of Akt/PKB by phosphoprotein 
phosphatase 2A (PP2A) is also illustrated. Activated Akt/PKB is a pleiotropic modulator of cell survival signaling pathways. Its target 
spectrum includes caspase-9 (Cas9) hereby causing its inhibition (please see Fig. 6 for further information) and the proapoptotic 
regulatory protein BAD, which otherwise could inactivate the antiapoptotic protein Bcl-XL and upregulate Mdm2, a modulatory protein 
responsible for the degradation of p53 (not shown) (please see Fig. 5 for information on p53). The Akt/PKB-dependent arrest of the cell 
cycle is attained by the upregulation of the cyclin kinase inhibitors p21cip1/waf1 and p27kip1 (please see also Fig. 2 for further information). 
Selected examples for roles of galectins (Gals) in this system are indicated (please see text for details).
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intracellular role of galectin-1 connected to oncogenic Ras, 
galectin-1, through binding to active Ras, has been shown 
to divert the EGFR-mediated activation not to the PI3K 
pathway but rather to the Raf-1/ERK pathway (175). When a 
galectin-3-negative cell line is transfected and overexpresses 
galectin-3, dephosphorylation of Akt/PKB is favored (207). 
This process is under the control of the phosphoprotein 
phosphatase 2A (PP2A) (please see Fig. 4). In this special cell 
system, galectin-3 appears to downregulate survival signals. In 
contrast, galectin-8, upon interaction with integrins, activates 
the PI3K-Akt/PKB and PI3K-p70 S6 kinase pathways, hereby 
increasing cell survival as well as cytoskeletal reorganization 
(144) (please see Figs. 3 and 4 for further details). These 
results teach us the salient lesson that different members of 
this lectin family can exert diverse functions on cells. It is 
indispensable, therefore, to monitor the galectin profile of 
a given cell type biochemically or immunohistochemically 
prior to reaching conclusions about the expected spectrum 
responses to a stimulus (94, 160, 208–221). The Akt/PKB 
pathway is also linked to the p53 activity spectrum. Therefore, 
we proceed to illustrate this aspect in the next section.
F. p53 as a Master Regulator of Cell Survival
When defects in cells, for example caused during 
exposure to genotoxic hazards that damage DNA, accumulate 
beyond a limit, the tumor suppressor protein p53 (222–224) 
and other related proteins such as p73 and p63 come into 
action (please see Fig. 5). Damage of DNA by UV-light, 
X-rays and γ-radiation activates the DNA-dependent protein 
kinase (DNAPK) and the poly(ADPribose) polymerase 
(PARP), which are biochemical systems that upregulate/
activate p53. In the same manner, mutations responsible for 
chromosomal instability and alterations in the DNA repair 
systems, as occurring in the Fanconi anemia syndrome 
(FAS), the Nijmegen breakage syndrome (NBS), the ataxia 
telangiectasia mutation (ATM) or Bloom
,
s syndrome 
(BLS), generate a series of gene products that alert the p53 
system. The tetrameric p53 acts as a transcription factor that 
upregulates the expression of proteins controlling the cell 
cycle such as the CKI p21cip1 (please see also Fig. 2), and 
proteins required for the entry of the cell into apoptosis, such 
as the proapoptotic regulatory protein Bax, and the death 
receptors Fas and DR5 (please see also Fig. 6). The action of 
p53 is kept in check by the modulatory protein Mdm2 (please 
see also Fig. 4, bottom). Mdm2 controls the proteolytic 
degradation of p53 by an ubiquitin-dependent pathway under 
normal conditions. After p53 activation, however, Mdm2 
loses its activity, hereby facilitating unimpeded transcriptional 
upregulation of genes controlling cell cycle arrest and 
apoptosis as well as the actual transcription of Mdm2 itself 
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Fittingly, absence or malfunction of p53 in many human tumor 
cells is directly responsible for their malignant properties. 
When examining p53-dependent alteration of transcriptional 
profile in DLD-1 colon cancer cells prior to the onset of 
apoptosis, 14 out of 7,202 transcripts were identiﬁ ed, among 
them that for galectin-7 (178). It is noteworthy in this respect 
to recall that this galectin is referred to as p53-induced gene 
1, as we have mentioned above in section C. In line with 
this result from serial analysis of gene expression (SAGE) 
screening, p53-dependent overexpression of galectin-7 
results in apoptotic cell death of keratinocytes upon UV-light 
exposure, a model system mimicking sunburn lesions (226), 
research that could have its implication in melanomagenesis 
when this system fails. Galectin-7 is also a negative growth 
regulator for neuroblastoma cells, where ganglioside GM1
is the surface target (48, 179, 227). The connection between 
galectins and the tumor suppressor p53 is further strengthened, 
because the chimera-type galectin-3 can be also a target for 
p53-dependent regulation, as brieﬂ y noted above in section C. 




























     chromosomal
        instability












Fig. 5. Signaling by the tumor suppressor p53. DNA damage by ionizing radiation (i.e. UV light, X-rays, γ-rays) or mutations 
resulting in chromosomal instability and/or failure in DNA repair, among other genotoxic stresses, induce the activation of p53 
expression. Mediators of this process are the DNA-dependent protein kinase (DNAPK) and the poly(ADP-ribose) polymerase (PARP). 
They can be activated by broken DNA strands or a series of altered gene products as for example those responsible for the Fanconi 
anemia syndrome (FAS), the Nijmegen breakage syndrome (NBS), the ataxia telangiectasia mutation (ATM) or Bloom
,
s syndrome 
(BLS). The p53-dependent transcriptional upregulation of the cyclin kinase inhibitor p21cip1/waf1 induces the arrest of the cell cycle at 
the G1/S transition (please see also Fig. 2). The transcriptional upregulation of the genes for the proapoptotic regulatory protein Bax 
and the death receptors Fas and DR5, among other proteins, paves the way toward apoptosis (please see also Fig. 6 ). The regulatory 
protein Mdm2 is involved in the degradation of p53 after its ubiquitination, at the same time that its transcriptional upregulation is 
under the control of p53. The upregulation of galectin-7 (Gal-7), referred to as p53-induced gene 1, by this system is indicated (please 
see text for details).
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coding ecomomy. Intriguingly, the second intron of this gene 
harbors a p53-regulatable promoter for an internal gene with 
an out-of-frame coding sequence relative to galectin-3 (228, 
229). A product of this gene, which is termed galig, promotes 
cytochrome c release, hereby achieving the status of a cell 
death gene antagonized by Bcl-XL overexpression (230). 
These events drive the cell into apoptosis/anoikis, guiding us 
to look more closely at signaling cascades directed toward 
programmed cell death in the next section.
G. Cell Death
Programmed cell death by apoptosis/anoikis has 
become a pervasive theme in studies of cell biology, reﬂ ecting 
the fundamental position of these mechanisms for the 
physiological cell fate. Matching this prominent position, 
various signaling cascades have a bearing on starting the 
route toward this kind of cell death. As examples from our 
set of already discussed ﬁ gures, small G proteins and MAPK 
pathways, distinct transcription factors, PI3K and tumor 
suppressors such as p53 or pRb are connected to the induction 
of apoptosis (231). When the contact to the extracellular 
matrix is essential and this contact is lost, the cells are subject 
to anoikis, a distinct version of apoptosis (232). Since the 
signals that induce cell death are multifarious, there are 
different principal routes to run through the process to induce 
apoptosis (233–235) (please see Fig. 6). Globally, the classical 
extrinsic pathway engages a subset of tumor necrosis factor 
(TNF) receptors, so-called death receptors, and their ligands 
(236–238). In addition, the intrinsic or mitochondria-mediated 
route can be induced by a variety of apoptogenic stimuli (239, 
240). A third way to attain programmed cell death, coined 
collectively as paraptosis, apoptosis-like cell death or non-
classical apoptosis, is also operative. It includes the caspase-
2-dependent pathway induced by DNA-damaging agents 
with ensuing participation of mitochondria (241, 242) and the 
caspase-independent pathway mediated by perforin/granzymes 
and an endoplasmic reticulum-located signaling machinery 
(243).
The balance between cell survival and apoptosis is 
under strict and delicate control. Inasmuch as normal cells 
rely on the action of multiple systems to control apoptosis, 
dysfunction of these regulatory mechanisms will result in 
resistance to apoptosis/anoikis and subsequent tumorigenesis 
and tumor progression (244–246). In general, the apoptotic 
pathways can share common signaling components, and 
crosstalk between them occurs to a significant extent. In 
order to introduce major constituents and the interconnection 
of the classical extrinsic receptor-mediated and the intrinsic 
mitochondria-mediated routes to the readers, Fig. 6 provides 
an overview of the caspase system which comprises central 
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(247, 248). As mentioned above, proteases of the granzyme 
type are also operative in caspase-independent mechanisms 
(249, 250). Two sets of caspases are assigned to the task 
to initiate the intracellular cascade of proteolysis and to 
actually account for enzymatic cleavage of cell constituents. 
Thus, multiple target proteins, denoted death substrates, are 
processed. To name a few and the obvious consequences 
of processing, the inhibitor of the caspase-activated DNase 
(ICAD) promoting DNA cleavage, nuclear lamins resulting 
in chromatin condensation, and integrity of the cytoskeletal 
regulatory and structural proteins (including gelsolin, plectin, 
focal adhesion kinase, p21-activated kinase 2, Rho kinase 
1, keratins and actin) are impaired inducing the collapse 
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Fig. 6. The extrinsic and intrinsic apoptosis pathways. The extrinsic apoptosis pathway is initiated by the respective 
activation of death receptors such as Fas/CD95 by the Fas ligand (FasL) and DR4/5 by the tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL). This process entails the recruitment of the adaptor Fas-associated death domain protein (FADD). 
The resulting signaling complex recruits procaspases 8 and 10 (prCas8 and prCas10), which are then converted to their active 
species caspases 8 and 10 (Cas8 and Cas10) by auto(trans)proteolysis. The formation of the initiator Cas8 enables to turn the inactive 
procaspases 3, 6 and 7 (not shown) into their corresponding active forms (Cas3, Cas6 and Cas7). These executioners or effector 
caspases degrade a large group of target proteins, referred to as death substrates, a salient step toward completing apoptotic cell 
death (please see text). The intrinsic apoptosis pathway centrally involves mitochondria. By disturbing their membrane potential, 
proapoptotic (+) regulatory proteins (Bax, Bad, and Bak, among others) trigger the release of several mitochondrial compounds 
including cytochrome c (cyt c). In the cytosol, cyt c associates with procaspase 9 (prCas9) and the apoptosis-activating factor-1 (Apaf-1) 
to build apoptosomes. They are the source of active caspase 9 (Cas9). Cas9 (functionally equivalent to Cas8 and Cas10, please see 
above) is an initiator protease that accounts for generating the effectors Cas3, Cas6 and Cas7 from their functionally silent precursors. 
Additional proteins released from the mitochondria are the apoptosis-inducing factor (AIF) and endonuclease G (EndoG). The former 
participates in chromatin condensation, and the latter rather likely in DNA degradation. Antiapoptotic (-) regulatory proteins such 
as Bcl-2 and Bcl-XL counteract the intrinsic pathway. Crosstalk between the extrinsic and intrinsic pathways is possible through the 
regulatory protein Bid. Upon its proteolysis by Cas8, Bid is translocated to the mitochondria, where it can promote the release of cyt c. 
Selected examples for roles of galectins (Gals) in this system are indicated (please see text for details).
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details on integrin-mediated cytoskeleton dynamics). As a 
consequence, the fragmentation of DNA, the condensation 
of chromatin, plasma membrane blebbing, cell shrinkage and 
the final formation of apoptotic bodies, which are removed 
by phagocytes without any inflammatory reaction, are the 
major hallmarks of the apoptotic process. Interestingly, lectin-
mediated mechanisms have been implicated in phagocytic 
clearance of apoptotic neurons by microglia, apoptotic 
leukemic cells by macrophages and of apoptotic neutrophils 
by alveolar macrophages (251–254). The surfactant collectins 
A and D can even home in on DNA present on apoptotic cells, 
clearing this cell debris and preventing inflammation (255). 
Equally interesting, lectins are inducers of apoptosis (please 
see Fig. 6 for details).
In studies to explore the functionality of galectin-1 in 
the immune system its beneficial effect in two autoimmune 
d i sease mode l s (myas then ia g rav i s in r abb i t s and 
encephalomyelitis in rats) pointed to a role of this galectin 
in affecting the T cell population (135, 256). The detection 
of this lectin in normal and malignant T cells (257), the 
10-fold upregulation of its mRNA in a leukemic T cell line 
(CEM) during glucocorticoid-induced apoptosis (258) and 
the demonstration of induction of apoptosis in activated T 
cells (73, 259–261) with clinical relevance for its contribution 
to certain diseases such as the Sézary syndrome or acquired 
immunodeficiency syndrome (AIDS) (262, 263) guided to 
the question on intracellular signaling following the initial 
binding of galectin-1 to the partner in the death pair, i.e. CD7 
(264) and the T-cell receptor (TCR) complex (265). To clarify 
the intriguing target specificity of the galectin despite the 
presentation of a large variety of β-galactosides, the recently 
available crystal structure of this immunomodulatory effector 
can serve as template to dock the target glycans (266). In 
fact, sites different from the galactose residue in contact with 
the central Trp ring system in the binding site can explain 
exquisite target selection (219, 227, 267). At the level of the 
target cell, the latter process results in activation of the ERK2 
pathway (please see Fig. 1 for more details) (265) and of the 
AP-1 transcription complex as well as the downregulation 
of Bcl-2 (268). Moreover, the characteristic rapid exposure 
of phosphatidylserine on the outer layer of the cell plasma 
membrane, an additional typical sign of apoptosis, has been 
observed in cells treated with galectin-1 (264, 269). How 
caspases come into play in galectin-induced apoptosis is 
explained in the next paragraph.
Fig. 6 summarizes important aspects of the signaling 
cascades involved in apoptosis. Caspases-3, -8 and -9 
showed increased activity in human and murine T cells after 
activation by galectin-1 (270, 271). The versatile way on how 
even closely related galectins differ in effector properties is 








































チン -1で活性化された後、カスパーゼ -3、-8、および -9の活
性が上昇する（270､271）。ガレクチン -2を調べると、ガレク
チンファミリーの一員であっても、個々の効果には違いがあ
ることがわかる。ガレクチン -2は CD3/CD7 とは反応できな
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galectin fails to react with CD3/CD7, a remarkable case 
for a qualitative difference in target selection between two 
closely related effectors, and activates a different spectrum of 
caspases with caspases-3 and -9 as major components (271). 
Galectin-7 treatment, in contrast, activates caspases-1, -3 and 
-8, in accord with differences in aggregation of various types 
of blood cells by galectins-1 and -7, while the tandem-repeat-
type galectin-9 exploits the Ca2+-calpain-caspase-1 pathway 
(271–273). In the case of galectin-2, the detection of opposite 
regulation by increasing the presence of pro-apoptotic Bax 
versus antiapoptotic Bcl-2, disruption of the mitochondrial 
membrane potential and release of cytochrome c are strong 
reasons to attribute this galectin-induced apoptosis to the 
intrinsic pathway (271). Of note, the chimera-type galectin-3 
is also an inducer of CD7-dependent apoptosis via cytochrome 
c release and caspase-3 activation (274). Cell surface cross-
linking of glycan ligands, made possible by the small extent of 
pentamer formation (65, 140, 275), is likely important in this 
case, whereas galectin-3 blocks inhibition of cell growth by 
homodimeric lectins in neuroblastoma cells (276). As noted 
above, galectins are effectors on the surface and in different 
compartments within the cells.
In the cell, galectin-3 has the ability to function as 
an anti-apoptotic molecule. The binding capacity to peptide 
motifs highlighted above is crucial for this activity. The 
protective action of galectin-3 concerns nitric-oxide-induced 
apoptosis of breast adenocarcinoma cells (277), C2-ceramide-
induced apoptosis (274) and nucling-mediated apoptosis, as 
cells from KO mice deficient in this apoptosome-associated 
molecule and cells overexpressing galectin-3 are resistant to 
pro-apoptotic stress (169). The protective action of galectin-3 
on nitric-oxide-induced apoptosis deserves further studies. Of 
note, nitric oxide is a versatile effector with a wide spectrum 
in ways to be functional such as arresting cell proliferation 
due in part to the reversible S-nitrosylation of the EGFR (278
–280), activating the p38MAPK pathway and inhibiting a 
p38MAPK-regulated phosphotyrosine phosphatase which 
dephosphorylates the active EGFR (280). Leukemic T cells 
transfected with galectin-3 become resistant to apoptosis 
by a process that includes the interaction of galectin-3 with 
Bcl-2 (194). In contrast, galectin-3 can promote TRAIL-
induced apoptosis in transfected breast adenocarcinoma cells 
by favoring Akt dephosphorylation, as described previously 
(please see Fig. 4), most likely through a redox mechanism 
in which glutathione is implicated (206). Therefore, cell 
type and its physiological context are important factors to 
be reckoned with precluding to reach reliable predictions 
easily. Regarding the technical approach it is also necessary 
to keep an eye on other properties of cells subjected to 
transfection. Breast adenocarcinoma cells with increased 
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the expression of α4β7 integrin is elevated, a property quite 
reasonably relevant also for cell survival (281). After all, 
integrin presentation, highlighted above, can be a decisive 
factor for apoptosis/anoikis regulation. Looking at galectin-7, 
its intracellular presence is linked to cytochrome c release 
and caspase-3 activation (180), indicating a similarity of 
effector functions at different sites for this galectin. When 
the profile of gene expression for galectin-7-overexpressing 
HeLa cells was monitored, upregulation of an integrin subunit 
(α1) and also α2,6-sialyltransferase, which synthesizes a cap 
for galectin ligands (89, 282), was detected, two proteins 
with potential impact on adhesion and galectin susceptibility 
(180). As listed in Table I, cell adhesion is a process where 
protein-carbohydrate recognition clearly rivals protein-protein 
recognition in importance (42, 283).
In addition to galectins, the C-type lectin group of 
selectins is essential for lymphocyte homing, and it has 
thus become a target for drug design (284). Because the 
initial intercellular contact is swiftly followed by leukocyte 
migration, cell interaction with selectin ligands should convey 
more information than just the docking process, as already 
attested by its inﬂ uence on signaling which we brieﬂ y outlined 
in the chapter on cell cycle control. Using site-specific 
inhibitors for signal transducers, a valuable tool also for 
analysis of signaling for plant-lectin-mediated cell aggregation 
(285, 286), and reagents to pinpoint changes in signaling 
cascades such as antibodies for distinct phosphoproteins, 
effects of selectin-carbohydrate interaction have been 
delineated for the leukocyte and the endothelial cell as will be 
discussed in the next section.
H. Selectin-Induced Signaling during Leukocyte/
Endothelial Cell Interaction
Leukocyte trafﬁ cking encompasses sugar-code-guided 
migration to sites of inflammation or entry into lymphatic 
tissues. Contact and transient attachment of leukocytes to 
endothelial cells of the vessel wall are prerequisites for ﬁ rm 
adhesion and extravasation (86, 96, 287). The mechanics of 
binding is suited to establish a molecular brake for the cells 
in blood flow, a process mediated by selectin recognition 
of distinct ligands (96, 288–292). The key molecular event 
underlying the initial process is the interaction of selectins with 
sialylated/sulfated determinants of Lewis blood group epitopes 
(90, 96, 283, 293, 294). The high degree of diversiﬁ cation of 
sulfotransferases, brieﬂ y noted in the introduction, with tasks 
in generating potent selectin determinants is another clear 
case of mutual complexity for a biological purpose, allowing 
us to give further credit to the concept of the sugar code 
(42, 295–297). Two in vivo lines of evidence are promising 
indicators that this research area is a fertile ﬁ eld for potential 
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immune defence in mice deficient for glycosyltransferases 
participating in synthesis of selectin ligands and b) the reduced 
fucosylation resulting from mutation in a gene encoding a 
GDP-fucose transporter as cause for immunodeﬁ ciency in the 
congenital disease named leukocyte adhesion deﬁ ciency II (19, 
298–301). Moreover, the detection of binding sites for Lewis 
epitopes on colon cancer cells points to engagement of these 
determinants as signals also for tumor cells (302). Having 
introduced the cell biological and structural aspects of selectin 
binding, we can proceed to epitomize the interplay at the cell 
surface as depicted in Fig. 7.
L-Selectin (CD62L) is positioned in the leukocyte 


































Fig. 7. Signaling mediated by selectins. The interaction of leukocyte L-selectin (L-SEL) with ligands located in the 
endothelial cell plasma membrane including sialomucin antigen CD34, mucosal addressin cell adhesion molecule-1 (MadCAM-1) 
and glycoprotein gp200 as well as with the extracellular glycosylated cell adhesion molecule-1 (GlyCAM-1) triggers a series of 
signaling events in leukocytes. They lead for example to increases of the cytosolic concentration of the free calcium ion ([Ca2+]cyt), 
potentiation of the oxidative burst generating anion superoxide (O2
·-) and hydrogen peroxide (H2O2), interaction with the urokinase 
plasminogen activator receptor (uPAR), activation of the cytosolic tyrosine kinase p56lck and stimulation of the Ras/mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, the Rac/Jun N-terminal kinase (JNK) pathway and 
the p38MAPK pathway (please see Fig. 1 for further information). This latter route in turn increases the binding afﬁ nity of integrins 
(INTs) to extracellular matrix glycoproteins. On the endothelial cell side, signaling depends on the interaction of P-selectin (P-SEL) 
with its leukocyte ligands P-selectin glycoprotein ligand-1 (PSGL-1) and the adhesion molecule CD24 as well as on the interaction 
of E-selectin (E-SEL) with its leukocyte ligand E-selectin ligand-1 (ESL-1) and also PSGL-1. Both E- and P-selectins activation 
have been shown to increase the [Ca2+]cyt. P-selectin engagement results in autophosphorylation, activation of the focal adhesion 
kinase (FAK) and tyrosine phosphorylation of paxillin (Pxl) (please see also Fig. 3 for additional information on FAK). E-selectin, 
in addition, has been shown to be phosphorylated by a tyrosine kinase (TK). Presence of this new determinant (the phosphotyrosine 
residues) recruits the SH2-containing protein-tyrosine phosphatase 2 (SHP2). The Ras/MAPK(ERK) pathway is activated by SHP2 
through a molecular complex formed by the SH2-domain-containing α2-collagen-related (Shc) protein, the adaptor protein Grb2 and 
a GTP-exchanger factor named son-of-sevenless (Sos) which activates Ras. This G-protein is therefore an essential effector for the 












   ©2006 FCCA (Forum: Carbohydrates Coming of Age)
                                      Trends in Glycoscience and Glycotechnology
                                      Vol.18 No.99 (January 2006) pp.1–37
26
sensor for docking sites. The other modules in the mosaic-
like protein, i.e. the EGF-like domain and two complement 
regulatory-like units (six for E- and nine for P-selectins), 
position this C-type lectin domain distal from the membrane 
surface, in full accordance with a braking mechanism. 
Binding with sialomucin CD34, mucosal addressin cell 
adhesion molecule-1 (MadCAM-1) and glycoprotein gp200, 
all of them located in the endothelial cell plasma membrane, 
is spatially unimpeded (87, 90, 96, 292, 293). In addition, 
L-selectin interacts with extracellular glycosylated cell 
adhesion molecule-1 (GlyCAM-1), a peripheral addressin 
of mucin-like nature in specialized high endothelial venules 
(87, 96, 292). An emerging topic on selectins, as is likewise 
occurring in other C-type lectin groups such as the surfactant 
collectins, is the realization that expression of e.g. L-selectin 
is not as restricted as initially thought. Its presence in human 
trophoblasts is a new aspect for implantation of the embryo in 
the uterus (96, 303). Also, L-selectin together with P-selectin 
(and also E-selectin) can be recruited to be involved in tumor 
spread (96, 304, 305). Signaling mechanisms are thus likely to 
be operative in other cell types beyond leukocytes/endothelial 
cells, the latter presenting E- and P-selectins.
E- and P-selectins are both engaged in the ligation 
of particular leukocyte glycoproteins. P-Selectin homes 
preferentially on P-selectin glycoprotein ligand-1 (PSGL-1) 
and the glycosylphosphatidylinositol-anchored surface 
mucin CD24, while E-selectin interacts with E-selectin 
ligand-1 (ESL-1) or also the PSGL-1 (87, 90, 283, 292, 293, 
306). PSGL-1 reaches its exquisite affinity by the strategic 
positioning of two tyrosine sulfates (tyrosine residues 7 
and 10), which add hydrogen bonding and stacking to 
the carbohydrate-mediated contact (307). Aside from the 
regulation of ligand synthesis their accessibility is subject to 
alteration by soluble selectins present in serum. In the case of 
P-selectin, this soluble form derived from shedding is involved 
in hemostasis after binding to leukocyte PSGL-1 triggering 
the release of tissue factors which engender thrombus 
formation (308). As indicated above, concerted action of 
glycosyltransferases and sulfotransferases is responsible for 
speciﬁ c posttranslational modiﬁ cations of different proteins to 
transform them into selectin ligands (290). The intimate way 
the sulfotransferases, which are responsible for generating the 
high-afﬁ nity ligands for selectins comparable to the synthesis 
of the antithrombin III-binding site in heparin, are regulated 
to orchestrate the display of the suitable ligands adds to the 
arguments for the sugar code concept given in the Introduction 
(295, 309, 310). In view of the explanations of basic concepts 
in biosignaling given in section B and most explicitly in the 
preceding sections, we will next look at principles of the 
intracellular responses to the carbohydrate-dependent docking 
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of the two cell types when encountering ligands for selectins.
On the leukocyte side, L-selectin engagement 
generates a transient increase in the cytosolic concentration 
of free Ca2+ ([Ca2+]cyt) and the oxidative burst associated with 
degranulation of neutrophils, the source of highly oxidant 
anion superoxide radical (O2·
-
) and hydrogen peroxide (H2O2) 
(85, 311, 312). Fluctuations of the Ca2+-level can be sensed 
by calmodulin, an ubiquitous intracellular calcium sensor 
in eukaryotic cells (313). Hereafter, the Ca2+/calmodulin 
complex interacts with the intracellular domain of L-selectin 
and is implicated in the regulation of selectin shedding 
following proteolytic cleavage (314). The Ca2+/calmodulin 
complex can also directly bind to tyrosine kinase receptors 
such as the EGFR, hereby negatively modulating its intrinsic 
tyrosine kinase activity (315–318), and to the ErbB2 receptor 
(319). This aspect reveals the versatile role of calmodulin as 
a transducer of the Ca2+ signal. As calmodulin is known to be 
phosphorylated by a variety of serine/threonine and tyrosine 
kinases including the EGFR (320), modulating the effector
,
s 
activity on multiple calmodulin-binding proteins (321), it will 
be pertinent to answer the question as to whether calmodulin 
phosphorylation could affect L-selectin shedding.
As further signals, tyrosine phosphorylation of 
multiple proteins and activation of the Ras/MAPK(ERK) 
pathway are associated with L-selectin ligation (312) (please 
see Fig. 1 for additional details). An effector for L-selectin-
dependent phosphorylation is the tyrosine kinase p56lck and 
the recruitment of a complex formed by the adaptor growth 
factor receptor-bound protein 2 (Grb2) and the GTP exchanger 
factor son-of-sevenless (Sos) which activates Ras (322) 
(please see Fig. 7). L-Selectin binding also stimulates JNK via 
p56lck and the small G proteins Rac1/2 (181). In addition, the 
ensuing activation of the p38MAPK pathway by L-selectin 
will eventually control leukocyte degranulation and integrin 
activation (183). As additional selectin binder, the urokinase 
plasminogen activator receptor (uPAR/CD87) directly 
associates with L-selectin, an interaction likely affecting 
uPAR-mediated pericellular proteolysis and leukocyte 
extravasation (323). The mentioned mechanisms are illustrated 
in Fig. 7, also letting the convergence of signaling pathways 
become apparent when Ras /MAPK(ERK) is depicted.
Looking at the vascular endothelium, the interaction 
of P- and E-selectins with their cognate ligands located in the 
leukocyte plasma membrane equally triggers signaling events. 
To be responsive the endothelial cells had to be activated by 
cytokines such as interleukin-1β (IL-1β) or tumor necrosis 
factor-α (TNF-α) and other proinflammatory stimuli, for 
example bacterial endotoxins, to present these selectins at 
the cell surface. Cell surface expression is regulated at the 
transcriptional and cellular level to direct them from storage 
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L-selectin action, P/E-selectin-dependent transient increase 
in the [Ca2+]cyt, resulting in cytoskeletal reorganization 
due to formation of stress fibers, has been observed (324) 
(please see Fig. 3 for additional information), and E-selectin 
exploits the Ras/MAPK(ERK) pathway with upregulation 
of the transcription factor c-Fos (325) (please see Fig. 1 for 
additional information). The primary route of activation of the 
Ras/MAPK(ERK) pathway is initiated by the phosphorylation 
of a distinct tyrosine residue in the short intracellular domain 
of E-selectin, the recruitment of the SH2-containing protein-
tyrosine phosphatase 2 (SHP2) to this phosphotyrosine residue 
and the bridging provided by a molecular complex formed 
with the adaptors SH2-domain-containing α2-collagen-
related (Shc) protein and Grb2 with the GTP exchanger factor 
Sos that activates Ras, a process evocative of L-selectin-
dependent mechanisms (326) (please see Fig. 7). On its part, 
P-selectin engagement induces tyrosine phosphorylation of 
different proteins including the autophosphorylation and 
activation of the focal adhesion kinase (FAK) and paxillin 
(Pxl), a focal adhesion-associated adaptor protein (327) 
(please see Fig. 3 and Fig. 7 for additional information). Pxl 
is also known to translocate to the nucleus where it may play 
a role in the regulation of gene transcription (328). Illustrating 
the vivid cross-talk between signaling routes with lectins 
as inducers, there is evidence for an interplay of selectin/
galectin recognition systems. The triggering of lymphocytes 
by L-selectin increases ligand presentation for galectin-3, 
hereby strengthening the contact to dendritic cells (329). 
This example points to the possibility to define new targets 
for a therapeutic intervention of undesirable cell contacts. In 
fact, efforts have been devoted to the development of speciﬁ c 
selectin inhibitors structurally related to the sialyl Lewisx 
determinant but yielding improved afﬁ nity (330, 331). They 
can be complemented by exploiting knowledge about post-
binding events. In this sense, the careful analysis of lectin-
dependent signaling has potential to define new targets to 
block an undesired activity in situations when the initial 
binding step cannot be impaired with sufﬁ cient speciﬁ city.
I. Concluding Remarks
We have started this review with the basic concept 
that the cell surface presents signals relevant for cell 
communication. The multitude of signals required for diverse 
responses calls for structurally rather compact units (messages) 
to fit into the limited space available. Their chemical 
properties endow carbohydrates with the unsurpassed capacity 
for high-density coding, and the elaborated enzymatic 
machinery for fine-tuned glycan assembly inspired the 
notion that the structure of the epitopes matters by bearing 
distinct information. Developmental and malignancy-
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be a signature-like phenomenological feature but a functional 
marker, utilizing the system of endogenous lectins as signal 
translator (please see Table I for summary of lectin functions). 
The lectin superfamily even harbors members which are either 
explicitly classiﬁ ed as growth factors or as cytokines such as 
basic ﬁ broblast growth factor (bFGF) or interleukin-2 (IL-2) 
(108, 332) or involved in growth factor activation such as the 
cation-independent mannose-6-phosphate receptor for TGF-β
as noted in section B (110). Signal presentation for lectins and 
the meaning of the messages can be modulated at different 
levels starting with their synthesis or transient modification 
and also encompassing topological aspects such as context of 
presentation. A major basic lesson to be learned is to consider 
cell surface glycoproteins as at least bifunctional molecules, 
with the protein and glycan parts acting as signalers.
Having introduced the two sides of information 
transfer in the sugar code, it is a major challenge to map the 
interaction of the binding partners structurally and to delineate 
the molecular chain of events from binding of the effector 
to completing the cellular response. Our review has focused 
on the latter aspect, illustrating crucial pathways in seven 
ﬁ gures deliberately tailored to focus on key elements. These 
ﬁ gures, too, point to arising insights into the way endogenous 
lectins trigger such cascades. It is fair to say that it is no 
longer a question whether but how lectins are operative at 
this level. Our presentation thus details advances for selected 
examples within the schemes. Moving beyond the individual 
pathways, it has become apparent that cross-talk between the 
different pathways is vivid. Depending on the nature of the 
signals which are being transmitted the flow of information 
can be subject to quantitative regulation or diverted into 
particular directions, in a way that can be summarized by the 
terms “contextual” and “combinatory”. The results of this 
analysis will not only have merit for their integration into the 
scheme hereby being continuously reﬁ ned. They also signify 
the identiﬁ cation of targets for intervention at early steps in 
signaling, in cases where it is difﬁ cult to hit the initial binding 
step. Alternatively, a lectin with known capacity to block 
signal ﬂ ow at a distinct site could be exploited to renormalize 
aberrant signaling. Toward this special end, the application 
of chemically designed mini-lectins constitutes a long-term 
aim, unless their target specificity is compromized by size 
reduction (333, 334). It is this emerging potential for fertile 
applications that connects the advances in our knowledge on 
lectin-dependent signaling with chemical/biochemical, cell 
biological and clinical aspects of glycosciences and inspires 
innovative approaches to rationally manipulate cell behavior.
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